Vanda Pharmaceuticals (VNDA) Gains FDA Approval to Proceed with IND for VSJ-110 for Allergic Conjunctivitis

Go back to Vanda Pharmaceuticals (VNDA) Gains FDA Approval to Proceed with IND for VSJ-110 for Allergic Conjunctivitis
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Delayed: 5.95 --0 (-0%)
Previous Close $5.95    52 Week High $18.00 
Open $5.95    52 Week Low $6.91 
Day High $5.95    P/E N/A 
Day Low $5.95    EPS $-0.67 
Volume 289